In addition, our studies revealed that protein over-expression of GRB7 is a stronger independent adverse prognostic factor than HER-2 over-expression (Ramsey et al. [2011]), a conclusion which is seemingly at odds with the widely held perspective of the role of HER-2 protein over-expression as the sole driver of adverse prognosis in chromosome 17q11-12 amplified breast tumors. Here, ERBB2 is linked to breast neoplasm.